Elevance Health, Inc. $ELV Shares Purchased by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S boosted its holdings in Elevance Health, Inc. (NYSE:ELV) by 11.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 145,408 shares of the company’s stock after buying an additional 15,294 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Elevance Health were worth $44,365,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Physician Wealth Advisors Inc. increased its holdings in shares of Elevance Health by 331.6% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock valued at $26,000 after acquiring an additional 63 shares during the last quarter. Activest Wealth Management boosted its holdings in Elevance Health by 66.7% in the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after purchasing an additional 34 shares in the last quarter. Vermillion & White Wealth Management Group LLC increased its stake in Elevance Health by 94.9% in the second quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock valued at $30,000 after purchasing an additional 37 shares during the last quarter. BOK Financial Private Wealth Inc. acquired a new stake in Elevance Health during the second quarter worth approximately $32,000. Finally, Motco lifted its position in shares of Elevance Health by 334.8% during the 3rd quarter. Motco now owns 100 shares of the company’s stock worth $32,000 after buying an additional 77 shares during the last quarter. 89.24% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $332.00 target price on shares of Elevance Health in a research report on Thursday, January 29th. JPMorgan Chase & Co. upped their price objective on shares of Elevance Health from $394.00 to $397.00 and gave the company an “overweight” rating in a research note on Monday. TD Cowen reiterated a “buy” rating on shares of Elevance Health in a research report on Wednesday, November 26th. Zacks Research raised Elevance Health from a “strong sell” rating to a “hold” rating in a report on Thursday, November 6th. Finally, Morgan Stanley dropped their price target on Elevance Health from $359.00 to $352.00 and set an “equal weight” rating on the stock in a research note on Wednesday, December 17th. Twelve research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $390.55.

Elevance Health Price Performance

Shares of NYSE:ELV opened at $340.34 on Thursday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.56 and a current ratio of 1.54. Elevance Health, Inc. has a one year low of $273.71 and a one year high of $458.75. The company has a 50-day simple moving average of $352.02 and a 200-day simple moving average of $329.67. The stock has a market capitalization of $75.64 billion, a price-to-earnings ratio of 13.55, a PEG ratio of 1.89 and a beta of 0.50.

Elevance Health (NYSE:ELV) last announced its earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating the consensus estimate of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The company had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. During the same period last year, the business posted $3.84 EPS. The company’s revenue was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, analysts predict that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be issued a $1.72 dividend. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $6.88 dividend on an annualized basis and a yield of 2.0%. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio is presently 27.23%.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.